- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| ROQUEFORT THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| Do | XFRA NEW INSTRUMENTS AVAILABLE ON 11.12.2025 | 133 | Xetra Newsboard | The following instruments on XETRA do have their first trading 11.12.2025 Die folgenden Instrumente in XETRA haben ihren ersten Handelstag 11.12.2025
Aktien
1 AU0000410128 Ariana Resources PLC
2... ► Artikel lesen | |
| Di | Roquefort Theraptcs. - Conversion of CLNs | - | RNS | ||
| 01.12. | Roquefort Therapeutics: Aktie handelt ab heute ex-Anspruch auf unkotierte Aktien | 1 | Investing.com Deutsch | ||
| 01.12. | Roquefort Therapeutics shares marked ex-entitlement for unlisted shares | 1 | Investing.com | ||
| 01.12. | Roquefort Theraptcs. - Ex-Entitlement Date - Unlisted RNV Shares | - | RNS | ||
| 01.12. | Roquefort Theraptcs. - Determination of Record Date and Entitlement | - | RNS | ||
| 24.11. | Director dealings: Roquefort Therapeutics director raises stake | 1 | Sharecast | ||
| 24.11. | Roquefort Theraptcs. - Director/PDMR Shareholding | - | RNS | ||
| 18.11. | Roquefort Theraptcs. - Executed License Agreement & Transaction Update | - | RNS | ||
| 03.11. | Roquefort Theraptcs. - MK Cell Out-License & Lyramid SPA Update | - | RNS | ||
| 16.10. | Roquefort Therapeutics beschafft 300.000 £ für Akquisition von Krebsmedikament | 1 | Investing.com Deutsch | ||
| 16.10. | Roquefort Therapeutics raises £300,000 to fund cancer drug acquisition | 2 | Investing.com | ||
| 16.10. | Roquefort Theraptcs. - Fundraise & Transaction Update | - | RNS | ||
| 30.09. | EARNINGS: Billington profit dives; Emmerson and Roquefort Therapeutics narrow loss | 1 | Alliance News | ||
| 30.09. | Roquefort Theraptcs. - Interim Results to 30 June 2025 | - | RNS | ||
| 24.09. | Roquefort Theraptcs. - Investor Presentation via Engage Investor | - | RNS | ||
| 08.09. | Roquefort Therapeutics shares surge on Coiled USA reverse takeover proposal | 1 | Alliance News | ||
| 08.09. | Roquefort Theraptcs. - Proposed Acquisition of Clinical Stage Company | - | RNS | ||
| 28.08. | Roquefort Therapeutics further extends deadline for Lyramid sale deal | 1 | Alliance News | ||
| 28.08. | Roquefort Theraptcs. - Lyramid SPA 2nd Extension & Carve Out | - | RNS |
1 2 Weiter >>
25 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| STRUCTURE THERAPEUTICS | 67,44 | -2,18 % | Structure Therapeutics Inc.: Structure Therapeutics Announces Pricing of Upsized $650 Million Public Offering of ADSs and Pre-Funded Warrants | SAN FRANCISCO, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for... ► Artikel lesen | |
| ARCELLX | 72,69 | +0,99 % | Stifel upgrades Arcellx stock, cites buying opportunity after share weakness | ||
| AVIDITY BIOSCIENCES | 71,60 | +0,35 % | Dyne upgraded at Oppenheimer on upcoming trial readout from Avidity | ||
| PRAXIS PRECISION MEDICINES | 267,28 | +2,18 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Announces Plans to File an NDA for Relutrigine in SCN2A and SCN8A Developmental and Epileptic Encephalopathies in Early 2026 | BOSTON, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies... ► Artikel lesen | |
| IMMUNOVANT | 24,810 | 0,00 % | Immunovant: 550-Millionen-Dollar-Kapitalerhöhung und neue Studiendetails | ||
| COGENT BIOSCIENCES | 40,040 | +2,22 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Positive Top-line Results of APEX Trial of Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM) | -- Bezuclastinib demonstrated rapid and deep clinical benefit in AdvSM patients resulting in an objective response rate (CR+CRh+PR+CI) of 57% per mIWG criteria and 80% per PPR criteria -- -- Bezuclastinib... ► Artikel lesen | |
| QIAGEN | 38,605 | -1,34 % | JEFFERIES stuft QIAGEN NV auf 'Buy' | NEW YORK (dpa-AFX Analyser) - Das Analysehaus Jefferies hat die Einstufung für Qiagen mit einem Kursziel von 57 US-Dollar auf "Buy" belassen. Die Profitabilität dürfte 2026 zumindest stabil bleiben... ► Artikel lesen | |
| TARSUS PHARMACEUTICALS | 81,70 | +0,47 % | Tarsus Pharmaceuticals, Inc: Tarsus Reports Third Quarter 2025 Financial Results and Recent Business Achievements | Delivered quarterly XDEMVY® net sales of approximately $119 million, up approximately 147% year-over-year Weekly multi-patient prescribers grew approximately 30% in the third quarter underscoring... ► Artikel lesen | |
| MOONLAKE IMMUNOTHERAPEUTICS | 14,070 | -3,70 % | Hagens Berman Sobol Shapiro LLP: MoonLake Immunotherapeutics' (MLTX) Stock Crashes 90%, Triggers Lawsuit After Reported Phase 3 Trial Data for Sole Drug Candidate -- Hagens Berman | SAN FRANCISCO, Nov. 28, 2025 /PRNewswire/ -- MoonLake Immunotherapeutics (NASDAQ: MLTX), a clinical-stage biotechnology company, has been hit with a securities... ► Artikel lesen | |
| DYNE THERAPEUTICS | 19,420 | -1,37 % | Dyne Therapeutics, Inc.: Dyne Therapeutics Announces Positive Topline Results from Phase 1/2 DELIVER Trial of Z-Rostudirsen in Duchenne Muscular Dystrophy (DMD) | - Registrational Expansion Cohort (REC) met primary endpoint, demonstrating statistically significant increase in dystrophin to 5.46% at 6 months (muscle content-adjusted; p - Functional improvement... ► Artikel lesen | |
| VERA THERAPEUTICS | 46,020 | +3,79 % | Vera Therapeutics, Inc. - 8-K, Current Report | ||
| MINERALYS THERAPEUTICS | 36,050 | -0,41 % | Mineralys Therapeutics, Inc.: Mineralys Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update | - Submission of New Drug Application (NDA) for lorundrostat planned for late-2025/Q1 2026 - - Completed enrollment in Explore-OSA trial; topline results anticipated in Q1 2026 - - Conference call... ► Artikel lesen | |
| FULCRUM THERAPEUTICS | 12,800 | -7,25 % | Fulcrum Therapeutics, Inc.: Fulcrum Therapeutics Announces Positive Initial Results from the 20 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease at the 67th American Society of Hematology Annual Meeting | ? Clear dose-response observed, with a robust and clinically meaningful fetal hemoglobin (HbF) induction at the Week 6 timepoint (n=12): mean absolute HbF in the 20 mg cohort increased by 9.9% at... ► Artikel lesen | |
| KYMERA THERAPEUTICS | 87,81 | 0,00 % | Kymera Therapeutics, Inc.: Kymera Therapeutics Announces U.S. FDA Fast Track Designation for KT-621, a First-in-Class, Oral STAT6 Degrader for the Treatment of Atopic Dermatitis | Fast Track designation supported by positive results from the KT-621 BroADen Phase 1b atopic dermatitis (AD) patient trial KT-621 BROADEN2 Phase 2b AD trial ongoing, with data expected to be reported... ► Artikel lesen | |
| OLEMA PHARMACEUTICALS | 31,550 | 0,00 % | Olema Pharmaceuticals stock price target raised to $45 at H.C. Wainwright |
ROQUEFORT THERAPEUTICS PLC gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 0,011 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ROQUEFORT THERAPEUTICS PLC finden Sie auf Wallstreet Online.